ESR2 and breast carcinoma: As shown above, most studies indicated the suppressive role of ER-β in TNBC, specifically, with mutant TP53; however, Ma et al. recently showed the absence of ER-α and upregulation of ER-β in breast cancer stem cells (BSCs).